Abstract
Get full access to this article
View all access options for this article.
References
1.
Knip
M
,
Virtanen
SM
,
Seppä
K
,
Ilonen
J
,
Savilahti
E
,
Vaarala
O
,
Reunanen
A
,
Teramo
K
,
Hämäläinen
AM
,
Paronen
J
,
Dosch
HM
,
Hakulinen
T
,
Akerblom
HK
. Finnish TRIGR Study Group. Dietary intervention in infancy and later signs of beta-cell autoimmunity . New Engl J Med , 2010 ; 363 : 1900 –1908 .
2.
Keymeulen
B
,
Vandemeulebroucke
E
,
Ziegler
AG
,
Mathieu
C
,
Kaufman
L
,
Hale
G
,
Gorus
F
,
Goldman
M
,
Walter
M
,
Candon
S
,
Schandene
L
,
Crenier
L
,
De Block
C
,
Seigneurin
JM
,
De Pauw
P
,
Pierard
D
,
Weets
I
,
Rebello
P
,
Bird
P
,
Berrie
E
,
Frewin
M
,
Waldmann
H
,
Bach
JF
,
Pipeleers
D
,
Chatenoud
L
. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes . New Engl J Med , 2005 ; 352 : 2598 –608 .
3.
Keymeulen
B
,
Walter
M
,
Mathieu
C
,
Kaufman
L
,
Gorus
F
,
Hilbrands
R
,
Vandemeulebroucke
E
,
Van de Velde
U
,
Crenier
L
,
De Block
C
,
Candon
S
,
Waldmann
H
,
Ziegler
AG
,
Chatenoud
L
,
Pipeleers
D
. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass . Diabetologia , 2010 ; 53 : 614 –623 .
4.
Keymeulen
B
,
Candon
S
,
Fafi-Kremer
S
,
Ziegler
A
,
Leruez-Ville
M
,
Mathieu
C
,
Vandemeulebroucke
E
,
Walter
M
,
Crenier
L
,
Thervet
E
,
Legendre
C
,
Pierard
D
,
Hale
G
,
Waldmann
H
,
Bach
JF
,
Seigneurin
JM
,
Pipeleers
D
,
Chatenoud
L
. Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients . Blood , 2010 ; 115 :1145 –1155 .
5.
Long
SA
,
Rieck
M
,
Sanda
S
,
Bollyky
JB
,
Samuels
PL
,
Goland
R
,
Ahmann
A
,
Rabinovitch
A
,
Aggarwal
S
,
Phippard
D
,
Turka
LA
,
Ehlers
MR
,
Bianchine
PJ
,
Boyle
KD
,
Adah
SA
,
Bluestone
JA
,
Buckner
JH
,
Greenbaum
CJ
. Diabetes TrialNet and the Immune Tolerance Network. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function . Diabetes , 2012 ; 61 : 2340 –48 .